These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14747261)

  • 21. A case of lipoatrophy with insulin detemir.
    Del Olmo MI; Campos V; Abellán P; Merino-Torres JF; Piñón F
    Diabetes Res Clin Pract; 2008 Apr; 80(1):e20-1. PubMed ID: 18281121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early preprandial hypoglycemia after administration of insulin lispro.
    Iafusco D; Angius E; Prisco F
    Diabetes Care; 1998 Oct; 21(10):1777-8. PubMed ID: 9773751
    [No Abstract]   [Full Text] [Related]  

  • 23. Insulin-induced lipodystrophy and interest of insulin injection ports.
    Ben Abdelkrim A; Fathallah N; Omri M; Hasni Y; Khaldi S; Kacem M; Chaieb M; Ben Salem C; Maaroufi A; Ach K
    Therapie; 2019 Dec; 74(6):680-682. PubMed ID: 31088690
    [No Abstract]   [Full Text] [Related]  

  • 24. Insulin allergy and extensive lipoatrophy in child with type 1 diabetes.
    Beltrand J; Guilmin-Crepon S; Castanet M; Peuchmaur M; Czernichow P; Levy-Marchal C
    Horm Res; 2006; 65(5):253-60. PubMed ID: 16582568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic decompensation in pump users due to lispro insulin precipitation.
    Wolpert HA; Faradji RN; Bonner-Weir S; Lipes MA
    BMJ; 2002 May; 324(7348):1253. PubMed ID: 12028980
    [No Abstract]   [Full Text] [Related]  

  • 26. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoatrophy in a girl with type 1 diabetes: beneficial effects of treatment with a glucocorticoid added to an insulin analog.
    Swelheim HT; Westerlaken C; van Pinxteren-Nagler E; Bocca G
    Diabetes Care; 2012 Mar; 35(3):e22. PubMed ID: 22355025
    [No Abstract]   [Full Text] [Related]  

  • 28. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
    Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
    [No Abstract]   [Full Text] [Related]  

  • 30. Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes.
    Burge MR; Carey JD
    Diabetes Care; 2004 Jan; 27(1):275-6. PubMed ID: 14694005
    [No Abstract]   [Full Text] [Related]  

  • 31. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
    Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
    Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

  • 33. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 34. Rapid-acting insulin analogues: when randomized clinical trial results do not help.
    Home PD
    Diabet Med; 2000 Sep; 17 Suppl 2():6-8. PubMed ID: 11048825
    [No Abstract]   [Full Text] [Related]  

  • 35. Pan-insulin allergy and severe lipoatrophy complicating Type 2 diabetes.
    Tavare AN; Doolittle HJ; Baburaj R
    Diabet Med; 2011 Apr; 28(4):500-3. PubMed ID: 21392071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin lispro: a useful advance in insulin therapy.
    Heller S
    Expert Opin Pharmacother; 2003 Aug; 4(8):1407-16. PubMed ID: 12877647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in the treatment of type 1 diabetes in children.
    Danne T; Lange K; Kordonouri O
    Arch Dis Child; 2007 Nov; 92(11):1015-9. PubMed ID: 17954479
    [No Abstract]   [Full Text] [Related]  

  • 38. Distant site lipoatrophy: a rare complication of subcutaneous insulin therapy.
    Chakraborty PP; Biswas SN
    Postgrad Med J; 2016 Jan; 92(1083):57-8. PubMed ID: 26561591
    [No Abstract]   [Full Text] [Related]  

  • 39. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of hypoglycemic brittle diabetes with peripheral edema successfully managed by conversion from insulin lispro to insulin aspart.
    Tone A; Shikata K; Nakagawa K; Hashimoto M; Makino H
    Diabetes Res Clin Pract; 2008 Sep; 81(3):e15-6. PubMed ID: 18676048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.